Current Management of Juvenile Myelomonocytic Leukemia and the Impact of RAS Mutations

Pediatric Drugs, 04/25/2012

Cumulative evidence suggests that RAS mutations can be related to favorable clinical outcomes, and hematopoietic stem cell transplantation (HSCT) may not have to be a mandatory therapeutic option for a portion of patients with this mutation, although a consensus regarding genotype–based management has not yet been achieved. Further efforts toward identifying which patients who will do well without HSCT are required.

Print Article Summary Cat 2 CME Report